1
BARKLEY PMHNP CERTIFICATION EXAMINATION —
ADVANCED CLINICAL PROFICIENCY ASSESSMENT HIGH-
YIELD QUESTIONS WITH CORRECT ANSWERS–
GUARANTEED PASS
EXAMINATION BOOKLET — VERSION 4.2
TIME ALLOWED: 4 HOURS | 175 QUESTIONS
SECTION I: DIAGNOSTIC FORMULATION & DIFFERENTIAL DIAGNOSIS ACROSS THE LIFESPAN
(Questions 1-35)
Question 1
A 16-year-old male presents with a documented history spanning 4 years characterized by recurrent
physical aggression toward peers, deliberate destruction of school property resulting in three
suspensions, persistent truancy, nocturnal elopement from home on five documented occasions, and a
pattern of surreptitiously gaining access to female peers' residences contrary to parental directives.
During the clinical interview, he maintains a stoic presentation with minimal verbal output, periodically
smirking when discussing disciplinary consequences. Prior to establishing a diagnosis of conduct disorder
with adolescent-onset specifier, which of the following diagnostic entities requires the MOST rigorous
exclusion through longitudinal history and collateral informant data?
1. Borderline personality disorder with emerging features in adolescent presentation
2. Intermittent explosive disorder characterized by discrete episodes of aggressive impulsivity
3. Bipolar I disorder manifesting with chronic irritability and episodic behavioral dyscontrol
4. Adjustment disorder with disturbance of conduct temporally linked to an identifiable
psychosocial stressor
5. Oppositional defiant disorder characterized by a pattern of angry/irritable mood and defiant
behavior
Answer: 1. Borderline personality disorder with emerging features in adolescent presentation
Explanation: The differential diagnosis for conduct disorder in adolescents necessitates systematic
exclusion of bipolar spectrum disorders (particularly when episodic behavioral activation is
documented), intermittent explosive disorder (distinguished by circumscribed aggressive outbursts
,2
without the pervasive pattern of norm violation), substance-induced behavioral syndromes, and
adjustment disorders with conduct features (which demonstrate clear temporal correlation with
identifiable stressors). However, borderline personality disorder—while diagnosable in adolescents
when maladaptive personality features persist for ≥1 year—represents a fundamentally distinct
diagnostic construct characterized by identity disturbance, frantic efforts to avoid abandonment,
recurrent suicidal/self-mutilatory behaviors, affective instability, chronic emptiness, and transient
stress-related paranoid ideation. The patient's presentation demonstrates the hallmark features of
conduct disorder: aggression toward people/animals, property destruction, deceitfulness/theft, and
serious rule violations. While borderline personality disorder may be considered in differential diagnosis
when self-harm or affective instability predominates, it would be LEAST likely to be included as a
primary differential in this prototypical conduct-disordered presentation. Oppositional defiant disorder
is properly excluded as a diagnosis when criteria for conduct disorder are met, per DSM-5-TR
hierarchical exclusion conventions. Bipolar disorder and adjustment disorder require careful
consideration given overlapping symptomatology.
Question 2
A 43-year-old female with a 15-year history of recurrent major depressive disorder, currently in a
moderate-to-severe episode as evidenced by PHQ-9 score of 19, presents for medication management.
She reports early morning awakening (typically 03:30-04:00), significant psychomotor retardation
observable during the clinical encounter, diurnal mood variation with nadir in morning hours, and a 12-
pound unintentional weight loss over 8 weeks. Neurovegetative assessment and neuroendocrine
laboratory evaluation are initiated. Which of the following laboratory aberrations would be MOST
inconsistent with the pathophysiological profile expected in melancholic depression?
1. Blunted thyroid-stimulating hormone response to thyrotropin-releasing hormone stimulation
testing
2. Elevated 24-hour urinary free cortisol excretion with loss of normal circadian nadir
3. Diminished nocturnal growth hormone secretory amplitude on polysomnographic assessment
4. Elevated cerebrospinal fluid somatostatin concentration on lumbar puncture analysis
5. Dexamethasone non-suppression on standardized challenge testing
Answer: 4. Elevated cerebrospinal fluid somatostatin concentration on lumbar puncture analysis
Explanation: The neuroendocrine signature of melancholic major depressive disorder is characterized by
hypothalamic-pituitary-adrenal (HPA) axis hyperactivity manifesting as hypercortisolemia (elevated 24-
hour urinary free cortisol, dexamethasone non-suppression, elevated salivary cortisol), hypothalamic-
pituitary-thyroid (HPT) axis dysregulation with blunted TSH response to TRH stimulation despite normal
peripheral thyroid indices, and growth hormone secretory abnormalities including diminished nocturnal
pulsatile secretion and paradoxical diurnal hypersecretion. Somatostatin, a hypothalamic
tetradecapeptide that inhibits growth hormone and TSH release, is consistently DECREASED—not
elevated—in the cerebrospinal fluid of patients with major depressive disorder. This reduction in
somatostatinergic tone may contribute to the HPA axis disinhibition and growth hormone dysregulation
,3
observed in melancholic depression. Post-mortem studies and CSF analyses have repeatedly
demonstrated reduced somatostatin immunoreactivity in depressed patients, with normalization
following successful antidepressant treatment. The other options represent established neuroendocrine
markers of melancholic depression and would be expected findings in this clinical presentation.
Question 3
A 28-year-old male inpatient on an acute psychiatric unit has been placed on continuous 1:1 observation
status following active suicidal ideation with identified plan (hanging) and preparatory behaviors
(hoarding bed linens). The treatment team is reevaluating the appropriate level of observation intensity.
According to evidence-based suicide risk stratification protocols for inpatient psychiatric settings, which
of the following clinical scenarios would LEAST justify maintaining continuous visual observation with
line-of-sight monitoring during all activities including toileting and hygiene?
1. The patient exhibits psychomotor agitation and perceptual disturbances consistent with alcohol
withdrawal syndrome of moderate severity (CIWA-Ar score 16)
2. The patient verbalizes persistent suicidal ideation but articulates willingness to engage in
collaborative safety planning and has signed a written commitment to treatment statement
3. The patient demonstrates profound ambivalence regarding suicidal intent, alternately
expressing desire to live and die within the same clinical encounter
4. The patient is within 72 hours of admission and carries a diagnosis of major depressive disorder
with melancholic and psychotic features
5. The patient has a documented history of dissimulating suicidal intent during previous
admissions while surreptitiously acquiring means for self-harm
Answer: 2. The patient verbalizes persistent suicidal ideation but articulates willingness to engage in
collaborative safety planning and has signed a written commitment to treatment statement
Explanation: Suicide risk stratification in inpatient settings requires differentiation between static,
stable, dynamic, and protective factors. Continuous 1:1 observation (or "close observation" with 15-
minute checks as described in the stem) is indicated for patients demonstrating: (1) active suicidal
ideation with identified plan and preparatory behaviors, (2) inability/unwillingness to engage in
collaborative safety planning (including refusal or inability to meaningfully participate in a commitment
to treatment statement), (3) conditions that impair judgment and impulse control such as substance
intoxication or withdrawal states, (4) psychotic processes that may precipitate unpredictable behavior,
and (5) documented history of concealed suicidal preparation. However, a patient who demonstrates
genuine engagement in safety planning, articulates reasons for living, and voluntarily commits to a
treatment agreement—even while acknowledging persistent suicidal thoughts—represents a
MODERATE rather than severe acute risk and may be managed with standard 15-minute observation
protocols rather than continuous 1:1 monitoring. Importantly, "no-harm contracts" have limited
empirical support as standalone interventions and should be contextualized within comprehensive
safety planning. Ambivalence regarding suicidal intent is a hallmark feature of the suicidal state and
warrants heightened observation, not reduced monitoring intensity.
, 4
Question 4
A 23-year-old male presents for evaluation reporting a 9-day period characterized by: (1) markedly
reduced sleep requirement (averaging 2-3 hours nightly) without concomitant fatigue, (2) subjective
experience of racing cognitions described as "my thoughts are running a marathon in my head," (3)
increased goal-directed activity manifested by working 16-hour days on a novel entrepreneurial venture,
(4) engagement in unprotected sexual encounters with multiple unfamiliar partners met at drinking
establishments despite no prior pattern of sexual risk-taking, and (5) pressured speech with tangentiality
evident during the interview. The patient adamantly denies any lifetime history of substance use "not
even coffee or cigarettes" and has no prior psychiatric treatment history. Collateral information from his
roommate corroborates the acute behavioral change with return to euthymic baseline noted 2 days
prior to this appointment. Assuming this presentation meets DSM-5-TR criteria for a manic episode,
which of the following pharmacologic interventions would be MOST contraindicated as monotherapy
during the acute phase of treatment?
1. Olanzapine 10 mg PO qHS with titration based on clinical response and metabolic monitoring
2. Lithium carbonate 300 mg PO BID with target serum concentration of 0.8-1.2 mEq/L following
renal function assessment
3. Valproate extended-release 500 mg PO BID with target serum concentration of 85-125 mcg/mL
4. Bupropion XL 150 mg PO daily with planned titration to 300 mg daily
5. Risperidone 2 mg PO BID with monitoring for extrapyramidal symptoms
Answer: 4. Bupropion XL 150 mg PO daily with planned titration to 300 mg daily
Explanation: This patient presents with a clear syndromal manic episode meeting DSM-5-TR Criterion A
(distinct period of abnormally and persistently elevated, expansive, or irritable mood and persistently
increased goal-directed activity/energy) and Criterion B (decreased need for sleep, racing thoughts,
increased goal-directed activity, excessive involvement in high-risk pleasurable activities, and pressured
speech). The duration of 9 days exceeds the 7-day threshold required for manic episode diagnosis
(unless hospitalization occurs). Pharmacologic management of acute mania requires mood stabilizers
(lithium, valproate, carbamazepine) or second-generation antipsychotics (olanzapine, risperidone,
quetiapine, aripiprazole, ziprasidone, asenapine, cariprazine) with established antimanic efficacy.
Bupropion, a norepinephrine-dopamine reuptake inhibitor antidepressant, carries a substantial risk of
precipitating or exacerbating manic episodes, inducing rapid cycling, or triggering mixed states when
administered as monotherapy to patients with bipolar spectrum disorders. While antidepressants may
be cautiously employed as adjunctive treatment in bipolar depression (with concurrent mood stabilizer
or antipsychotic coverage), their use in acute mania is absolutely contraindicated as monotherapy.
Furthermore, bupropion's dopaminergic activity theoretically increases risk of psychotic symptom
emergence in vulnerable individuals. The 2018 CANMAT/ISBD guidelines recommend against
antidepressant monotherapy in bipolar I disorder and advise discontinuation of antidepressants during
manic episodes.
BARKLEY PMHNP CERTIFICATION EXAMINATION —
ADVANCED CLINICAL PROFICIENCY ASSESSMENT HIGH-
YIELD QUESTIONS WITH CORRECT ANSWERS–
GUARANTEED PASS
EXAMINATION BOOKLET — VERSION 4.2
TIME ALLOWED: 4 HOURS | 175 QUESTIONS
SECTION I: DIAGNOSTIC FORMULATION & DIFFERENTIAL DIAGNOSIS ACROSS THE LIFESPAN
(Questions 1-35)
Question 1
A 16-year-old male presents with a documented history spanning 4 years characterized by recurrent
physical aggression toward peers, deliberate destruction of school property resulting in three
suspensions, persistent truancy, nocturnal elopement from home on five documented occasions, and a
pattern of surreptitiously gaining access to female peers' residences contrary to parental directives.
During the clinical interview, he maintains a stoic presentation with minimal verbal output, periodically
smirking when discussing disciplinary consequences. Prior to establishing a diagnosis of conduct disorder
with adolescent-onset specifier, which of the following diagnostic entities requires the MOST rigorous
exclusion through longitudinal history and collateral informant data?
1. Borderline personality disorder with emerging features in adolescent presentation
2. Intermittent explosive disorder characterized by discrete episodes of aggressive impulsivity
3. Bipolar I disorder manifesting with chronic irritability and episodic behavioral dyscontrol
4. Adjustment disorder with disturbance of conduct temporally linked to an identifiable
psychosocial stressor
5. Oppositional defiant disorder characterized by a pattern of angry/irritable mood and defiant
behavior
Answer: 1. Borderline personality disorder with emerging features in adolescent presentation
Explanation: The differential diagnosis for conduct disorder in adolescents necessitates systematic
exclusion of bipolar spectrum disorders (particularly when episodic behavioral activation is
documented), intermittent explosive disorder (distinguished by circumscribed aggressive outbursts
,2
without the pervasive pattern of norm violation), substance-induced behavioral syndromes, and
adjustment disorders with conduct features (which demonstrate clear temporal correlation with
identifiable stressors). However, borderline personality disorder—while diagnosable in adolescents
when maladaptive personality features persist for ≥1 year—represents a fundamentally distinct
diagnostic construct characterized by identity disturbance, frantic efforts to avoid abandonment,
recurrent suicidal/self-mutilatory behaviors, affective instability, chronic emptiness, and transient
stress-related paranoid ideation. The patient's presentation demonstrates the hallmark features of
conduct disorder: aggression toward people/animals, property destruction, deceitfulness/theft, and
serious rule violations. While borderline personality disorder may be considered in differential diagnosis
when self-harm or affective instability predominates, it would be LEAST likely to be included as a
primary differential in this prototypical conduct-disordered presentation. Oppositional defiant disorder
is properly excluded as a diagnosis when criteria for conduct disorder are met, per DSM-5-TR
hierarchical exclusion conventions. Bipolar disorder and adjustment disorder require careful
consideration given overlapping symptomatology.
Question 2
A 43-year-old female with a 15-year history of recurrent major depressive disorder, currently in a
moderate-to-severe episode as evidenced by PHQ-9 score of 19, presents for medication management.
She reports early morning awakening (typically 03:30-04:00), significant psychomotor retardation
observable during the clinical encounter, diurnal mood variation with nadir in morning hours, and a 12-
pound unintentional weight loss over 8 weeks. Neurovegetative assessment and neuroendocrine
laboratory evaluation are initiated. Which of the following laboratory aberrations would be MOST
inconsistent with the pathophysiological profile expected in melancholic depression?
1. Blunted thyroid-stimulating hormone response to thyrotropin-releasing hormone stimulation
testing
2. Elevated 24-hour urinary free cortisol excretion with loss of normal circadian nadir
3. Diminished nocturnal growth hormone secretory amplitude on polysomnographic assessment
4. Elevated cerebrospinal fluid somatostatin concentration on lumbar puncture analysis
5. Dexamethasone non-suppression on standardized challenge testing
Answer: 4. Elevated cerebrospinal fluid somatostatin concentration on lumbar puncture analysis
Explanation: The neuroendocrine signature of melancholic major depressive disorder is characterized by
hypothalamic-pituitary-adrenal (HPA) axis hyperactivity manifesting as hypercortisolemia (elevated 24-
hour urinary free cortisol, dexamethasone non-suppression, elevated salivary cortisol), hypothalamic-
pituitary-thyroid (HPT) axis dysregulation with blunted TSH response to TRH stimulation despite normal
peripheral thyroid indices, and growth hormone secretory abnormalities including diminished nocturnal
pulsatile secretion and paradoxical diurnal hypersecretion. Somatostatin, a hypothalamic
tetradecapeptide that inhibits growth hormone and TSH release, is consistently DECREASED—not
elevated—in the cerebrospinal fluid of patients with major depressive disorder. This reduction in
somatostatinergic tone may contribute to the HPA axis disinhibition and growth hormone dysregulation
,3
observed in melancholic depression. Post-mortem studies and CSF analyses have repeatedly
demonstrated reduced somatostatin immunoreactivity in depressed patients, with normalization
following successful antidepressant treatment. The other options represent established neuroendocrine
markers of melancholic depression and would be expected findings in this clinical presentation.
Question 3
A 28-year-old male inpatient on an acute psychiatric unit has been placed on continuous 1:1 observation
status following active suicidal ideation with identified plan (hanging) and preparatory behaviors
(hoarding bed linens). The treatment team is reevaluating the appropriate level of observation intensity.
According to evidence-based suicide risk stratification protocols for inpatient psychiatric settings, which
of the following clinical scenarios would LEAST justify maintaining continuous visual observation with
line-of-sight monitoring during all activities including toileting and hygiene?
1. The patient exhibits psychomotor agitation and perceptual disturbances consistent with alcohol
withdrawal syndrome of moderate severity (CIWA-Ar score 16)
2. The patient verbalizes persistent suicidal ideation but articulates willingness to engage in
collaborative safety planning and has signed a written commitment to treatment statement
3. The patient demonstrates profound ambivalence regarding suicidal intent, alternately
expressing desire to live and die within the same clinical encounter
4. The patient is within 72 hours of admission and carries a diagnosis of major depressive disorder
with melancholic and psychotic features
5. The patient has a documented history of dissimulating suicidal intent during previous
admissions while surreptitiously acquiring means for self-harm
Answer: 2. The patient verbalizes persistent suicidal ideation but articulates willingness to engage in
collaborative safety planning and has signed a written commitment to treatment statement
Explanation: Suicide risk stratification in inpatient settings requires differentiation between static,
stable, dynamic, and protective factors. Continuous 1:1 observation (or "close observation" with 15-
minute checks as described in the stem) is indicated for patients demonstrating: (1) active suicidal
ideation with identified plan and preparatory behaviors, (2) inability/unwillingness to engage in
collaborative safety planning (including refusal or inability to meaningfully participate in a commitment
to treatment statement), (3) conditions that impair judgment and impulse control such as substance
intoxication or withdrawal states, (4) psychotic processes that may precipitate unpredictable behavior,
and (5) documented history of concealed suicidal preparation. However, a patient who demonstrates
genuine engagement in safety planning, articulates reasons for living, and voluntarily commits to a
treatment agreement—even while acknowledging persistent suicidal thoughts—represents a
MODERATE rather than severe acute risk and may be managed with standard 15-minute observation
protocols rather than continuous 1:1 monitoring. Importantly, "no-harm contracts" have limited
empirical support as standalone interventions and should be contextualized within comprehensive
safety planning. Ambivalence regarding suicidal intent is a hallmark feature of the suicidal state and
warrants heightened observation, not reduced monitoring intensity.
, 4
Question 4
A 23-year-old male presents for evaluation reporting a 9-day period characterized by: (1) markedly
reduced sleep requirement (averaging 2-3 hours nightly) without concomitant fatigue, (2) subjective
experience of racing cognitions described as "my thoughts are running a marathon in my head," (3)
increased goal-directed activity manifested by working 16-hour days on a novel entrepreneurial venture,
(4) engagement in unprotected sexual encounters with multiple unfamiliar partners met at drinking
establishments despite no prior pattern of sexual risk-taking, and (5) pressured speech with tangentiality
evident during the interview. The patient adamantly denies any lifetime history of substance use "not
even coffee or cigarettes" and has no prior psychiatric treatment history. Collateral information from his
roommate corroborates the acute behavioral change with return to euthymic baseline noted 2 days
prior to this appointment. Assuming this presentation meets DSM-5-TR criteria for a manic episode,
which of the following pharmacologic interventions would be MOST contraindicated as monotherapy
during the acute phase of treatment?
1. Olanzapine 10 mg PO qHS with titration based on clinical response and metabolic monitoring
2. Lithium carbonate 300 mg PO BID with target serum concentration of 0.8-1.2 mEq/L following
renal function assessment
3. Valproate extended-release 500 mg PO BID with target serum concentration of 85-125 mcg/mL
4. Bupropion XL 150 mg PO daily with planned titration to 300 mg daily
5. Risperidone 2 mg PO BID with monitoring for extrapyramidal symptoms
Answer: 4. Bupropion XL 150 mg PO daily with planned titration to 300 mg daily
Explanation: This patient presents with a clear syndromal manic episode meeting DSM-5-TR Criterion A
(distinct period of abnormally and persistently elevated, expansive, or irritable mood and persistently
increased goal-directed activity/energy) and Criterion B (decreased need for sleep, racing thoughts,
increased goal-directed activity, excessive involvement in high-risk pleasurable activities, and pressured
speech). The duration of 9 days exceeds the 7-day threshold required for manic episode diagnosis
(unless hospitalization occurs). Pharmacologic management of acute mania requires mood stabilizers
(lithium, valproate, carbamazepine) or second-generation antipsychotics (olanzapine, risperidone,
quetiapine, aripiprazole, ziprasidone, asenapine, cariprazine) with established antimanic efficacy.
Bupropion, a norepinephrine-dopamine reuptake inhibitor antidepressant, carries a substantial risk of
precipitating or exacerbating manic episodes, inducing rapid cycling, or triggering mixed states when
administered as monotherapy to patients with bipolar spectrum disorders. While antidepressants may
be cautiously employed as adjunctive treatment in bipolar depression (with concurrent mood stabilizer
or antipsychotic coverage), their use in acute mania is absolutely contraindicated as monotherapy.
Furthermore, bupropion's dopaminergic activity theoretically increases risk of psychotic symptom
emergence in vulnerable individuals. The 2018 CANMAT/ISBD guidelines recommend against
antidepressant monotherapy in bipolar I disorder and advise discontinuation of antidepressants during
manic episodes.
